The litigation centers on allegations that the pharmaceutical company misled shareholders regarding its business operations and the safety profile of its drug candidate, ARD-101. According to the complaint, the company allegedly overstated the regulatory and commercial prospects of the treatment while failing to disclose significant safety concerns during the specified class period.

Shareholders who wish to participate in the litigation must formally move the court by the October deadline. While Glancy Prongay Wolke & Rotter LLP is currently soliciting plaintiffs, investors maintain the right to retain alternative counsel or choose not to participate at all, as no class has been certified by the court at this stage. The firm, based in Los Angeles, states it is prepared to assist affected investors in pursuing recovery claims for their losses.